Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Trial Profile

Clofarabine Followed by Lenalidomide for Treatment of High Risk Myelodysplastic Syndromes and Acute Myeloid Leukemia

Completed
Phase of Trial: Phase I

Latest Information Update: 25 Oct 2017

At a glance

  • Drugs Clofarabine (Primary) ; Lenalidomide (Primary)
  • Indications Acute myeloid leukaemia; Chronic myeloid leukaemia; Chronic myelomonocytic leukaemia; Myelodysplastic syndromes
  • Focus Adverse reactions
  • Most Recent Events

    • 06 Dec 2016 Results assessing preliminary outcomes presented at the 58th Annual Meeting and Exposition of the American Society of Hematology.
    • 28 Oct 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
    • 07 Jul 2015 Planned End Date changed from 1 Jun 2015 to 1 Jun 2016 as reported by ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top